December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

66.20 -1.41 (-2.08%)
Streaming Delayed Price Updated: 10:42 AM EDT, Aug 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
92 93 Next >
News headline image
Is Bristol Myers Squibb Stock a Buy? ↗
Does Bristol Myers have the potential to be a market-beating stock? 
Via The Motley Fool
News headline image
Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma ↗
2seventy Bio finalized an asset purchase agreement with Novo Nordisk involving the Hemophilia A program and in vivo gene editing technology. The 2seventy bio team will join Novo Nordisk, focusing on... 
Via Benzinga
News headline image
You’ve Been Warned! 3 Pharma Stocks to Buy Now or Regret Forever. ↗
Pharmaceutical stocks can be considered risky, but when their trials get approved by FDA, the stock can go to the moon. 
Via InvestorPlace
News headline image
What the Options Market Tells Us About Bristol-Myers Squibb ↗
 
Via Benzinga
News headline image
FDA Approves Bristol Myers Squibb's Combination Therapy For Colorectal Cancer Patients With Certain Type Of Gene Mutation ↗
The FDA granted accelerated approval to Bristol Myers Squibb's Krazati (adagrasib) with cetuximab for adult patients with KRASG12C-mutated advanced or metastatic colorectal cancer. 
Via Benzinga
News headline image
Bristol-Myers Squibb Stock Price Forecast: Is The Downtrend Finally Over? ↗
Technical analysis suggests short-term support at $39.90; potential recovery to $56. 
Via Talk Markets
News headline image
This Is What Whales Are Betting On Bristol-Myers Squibb ↗
 
Via Benzinga
News headline image
Bristol-Myers Squibb's Options Frenzy: What You Need to Know ↗
 
Via Benzinga
News headline image
7 Dividend Stocks to Buy Now: June 2024 ↗
These dividend stocks to buy now will reward investors with income now and growth as the market breadth expands. 
Via InvestorPlace
News headline image
AbbVie Inc. Dividend Stock Analysis - Saturday, June 22 ↗
Here are some highlights from a detailed, quantitative analysis AbbVie Inc. stock. Let's take a closer look at various factors, such as the stock's value and dividend. 
Via Talk Markets
News headline image
S&P 500 Earnings Dashboard 24Q1 - Saturday, June 22 ↗
Of the 498 companies in the S&P 500 that have reported earnings to date for 24Q1, 78.7% reported above analyst expectations. This compares to a long-term average of 66%. 
Via Talk Markets
Topics Stocks
News headline image
3 No-Brainer Stocks to Buy for Under $100 Right Now ↗
You won't need much money to start investing in these great stocks. 
Via The Motley Fool
News headline image
3 High-Yield Dividend Stocks Near Their 52-Week Lows to Buy and Hold ↗
The pharmaceutical industry giants offer reliable profit growth and above-average dividend yields. 
Via The Motley Fool
News headline image
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
From Bristol Myers Squibb
Via Business Wire
News headline image
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments ↗
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments. 
Via Benzinga
News headline image
European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab
From Bristol Myers Squibb
Via Business Wire
News headline image
German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount ↗
Evotec consults defense advisers following a significant share price decline, raising concerns about a potential takeover. 
Via Benzinga
News headline image
Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024
From Bristol Myers Squibb
Via Business Wire
News headline image
3 Warren Buffett Stocks to Buy Now: June 2024 ↗
If you have a long-term view of the market, it’s a good time to look for some Warren Buffett stocks to buy now. 
Via InvestorPlace
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors
From Bristol Myers Squibb
Via Business Wire
News headline image
Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb ↗
These two pharma stocks are beloved by income investors. 
Via The Motley Fool
News headline image
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
News headline image
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline ↗
With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities. 
Via InvestorPlace
News headline image
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:BPTH),(NASDAQ:LGVN),(NASDAQ:SLS),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
3 High-Yield S&P 500 Dividend Stocks Down More Than 25% to Buy Now and Hold for at Least a Decade ↗
Their prices might not be done falling, but you can count on the dividends they distribute to continue rising steadily. 
Via The Motley Fool
Topics Stocks
News headline image
3 High-Yield Dividend Stocks for Income Now and Growth Later
Buying high-yield dividend stocks at a low price today gives you current income with the opportunity for growth when interest rates come down later this year 
Via MarketBeat
Topics Economy
News headline image
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
From FN Media Group LLC
Via GlobeNewswire
News headline image
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
From Bristol Myers Squibb
Via Business Wire
News headline image
3 Penny Stocks to Buy if You Want to Spend Less and Earn More ↗
These penny stocks to buy provide a good opportunity for investors to buy low-priced stocks that provide significant growth potential. 
Via InvestorPlace
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
92 93 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.